These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

362 related articles for article (PubMed ID: 19470455)

  • 21. Role of lenalidomide in the treatment of myelodysplastic syndromes.
    Komrokji RS; List AF
    Semin Oncol; 2011 Oct; 38(5):648-57. PubMed ID: 21943671
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pleiotropic mechanisms of action of lenalidomide efficacy in del(5q) myelodysplastic syndromes.
    Heise C; Carter T; Schafer P; Chopra R
    Expert Rev Anticancer Ther; 2010 Oct; 10(10):1663-72. PubMed ID: 20942636
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Lenalidomide--a transforming therapeutic agent in myelodysplastic syndromes.
    List A
    Clin Lymphoma Myeloma; 2009; 9 Suppl 3():S302-4. PubMed ID: 19778857
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Correlation of clinical response and response duration with miR-145 induction by lenalidomide in CD34(+) cells from patients with del(5q) myelodysplastic syndrome.
    Venner CP; Woltosz JW; Nevill TJ; Deeg HJ; Caceres G; Platzbecker U; Scott BL; Sokol L; Sung S; List AF; Karsan A
    Haematologica; 2013 Mar; 98(3):409-13. PubMed ID: 22929976
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Myelodysplastic syndromes del(5q): Pathogenesis and its therapeutic implications.
    Bruzzese A; Martino EA; Mendicino F; Lucia E; Olivito V; Capodanno I; Neri A; Morabito F; Vigna E; Gentile M
    Eur J Haematol; 2024 Jun; 112(6):860-869. PubMed ID: 38294126
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Genome-wide miRNA profiling in myelodysplastic syndrome with del(5q) treated with lenalidomide.
    Merkerova MD; Krejcik Z; Belickova M; Hrustincova A; Klema J; Stara E; Zemanova Z; Michalova K; Cermak J; Jonasova A
    Eur J Haematol; 2015 Jul; 95(1):35-43. PubMed ID: 25287904
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Lenalidomide does not increase AML progression risk in RBC transfusion-dependent patients with Low- or Intermediate-1-risk MDS with del(5q): a comparative analysis.
    Kuendgen A; Lauseker M; List AF; Fenaux P; Giagounidis AA; Brandenburg NA; Backstrom J; Glasmacher A; Hasford J; Germing U;
    Leukemia; 2013 Apr; 27(5):1072-9. PubMed ID: 23257782
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Biology and treatment of the 5q- syndrome.
    Padron E; Komrokji R; List AF
    Expert Rev Hematol; 2011 Feb; 4(1):61-9. PubMed ID: 21322779
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Deletion 5q MDS: molecular and therapeutic implications.
    Komrokji RS; Padron E; Ebert BL; List AF
    Best Pract Res Clin Haematol; 2013 Dec; 26(4):365-75. PubMed ID: 24507813
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical effect of increasing doses of lenalidomide in high-risk myelodysplastic syndrome and acute myeloid leukemia with chromosome 5 abnormalities.
    Möllgård L; Saft L; Treppendahl MB; Dybedal I; Nørgaard JM; Astermark J; Ejerblad E; Garelius H; Dufva IH; Jansson M; Jädersten M; Kjeldsen L; Linder O; Nilsson L; Vestergaard H; Porwit A; Grønbæk K; Hellström-Lindberg E
    Haematologica; 2011 Jul; 96(7):963-71. PubMed ID: 21719884
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Lenalidomide treatment of myelodysplastic syndromes with chromosome 5q deletion: Results from the National Registry of the Italian Drug Agency.
    Arcioni F; Roncadori A; Di Battista V; Tura S; Covezzoli A; Cundari S; Mecucci C;
    Eur J Haematol; 2018 Jul; 101(1):78-85. PubMed ID: 29569278
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Higher-risk myelodysplastic syndromes with del(5q): is sequential azacitidine-lenalidomide combination the way to go?
    Zeidan AM; Gore SD; Komrokji RS
    Expert Rev Hematol; 2013 Jun; 6(3):251-4. PubMed ID: 23782079
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Lenalidomide in the context of complex karyotype or interrupted treatment: case reviews of del(5q)MDS patients with unexpected responses.
    Giagounidis AA; Haase S; Heinsch M; Göhring G; Schlegelberger B; Aul C
    Ann Hematol; 2007 Feb; 86(2):133-7. PubMed ID: 17111142
    [TBL] [Abstract][Full Text] [Related]  

  • 34. High level of full-length cereblon mRNA in lower risk myelodysplastic syndrome with isolated 5q deletion is implicated in the efficacy of lenalidomide.
    Jonasova A; Bokorova R; Polak J; Vostry M; Kostecka A; Hajkova H; Neuwirtova R; Siskova M; Sponerova D; Cermak J; Mikulenkova D; Cervinek L; Brezinova J; Michalova K; Fuchs O
    Eur J Haematol; 2015 Jul; 95(1):27-34. PubMed ID: 25284710
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Early lenalidomide treatment for low and intermediate-1 International Prognostic Scoring System risk myelodysplastic syndromes with del(5q) before transfusion dependence.
    Oliva EN; Lauseker M; Aloe Spiriti MA; Poloni A; Cortelezzi A; Palumbo GA; Balleari E; Sanpaolo G; Volpe A; Ricco A; Ronco F; Alati C; D'Errigo MG; Santacaterina I; Kündgen A; Germing U; Latagliata R
    Cancer Med; 2015 Dec; 4(12):1789-97. PubMed ID: 26376955
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Lenalidomide: a review of its use in patients with transfusion-dependent anaemia due to low- or intermediate-1-risk myelodysplastic syndrome associated with 5q chromosome deletion.
    Syed YY; Scott LJ
    Drugs; 2013 Jul; 73(11):1183-96. PubMed ID: 23824699
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The role of lenalidomide in the management of myelodysplasia with del 5q.
    Kelaidi C; Eclache V; Fenaux P
    Br J Haematol; 2008 Feb; 140(3):267-78. PubMed ID: 18217896
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cytogenetic and molecular predictors of response in patients with myeloid malignancies without del[5q] treated with lenalidomide.
    Sugimoto Y; Sekeres MA; Makishima H; Traina F; Visconte V; Jankowska A; Jerez A; Szpurka H; O'Keefe CL; Guinta K; Afable M; Tiu R; McGraw KL; List AF; Maciejewski J
    J Hematol Oncol; 2012 Mar; 5():4. PubMed ID: 22390313
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Multivariate time-dependent comparison of the impact of lenalidomide in lower-risk myelodysplastic syndromes with chromosome 5q deletion.
    Sánchez-García J; Del Cañizo C; Lorenzo I; Nomdedeu B; Luño E; de Paz R; Xicoy B; Valcárcel D; Brunet S; Marco-Betes V; García-Pintos M; Osorio S; Tormo M; Bailén A; Cerveró C; Ramos F; Diez-Campelo M; Such E; Arrizabalaga B; Azaceta G; Bargay J; Arilla MJ; Falantes J; Serrano-López J; Sanz GF;
    Br J Haematol; 2014 Jul; 166(2):189-201. PubMed ID: 24716538
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Lenalidomide for treatment of myelodysplastic syndromes.
    Komrokji RS; List AF
    Curr Pharm Des; 2012; 18(22):3198-203. PubMed ID: 22571699
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.